The Alzheimer’s Prevention Study is for people with a specific genetic marker related to early onset Alzheimer’s Disease. To qualify, you need to meet the following requirements:
- 65 to 75 years of age in overall good health
- No current form of dementia or other cognitive impairment
- 1 or 2 copies of the APOE e4 gene (genetic testing and counseling are included)
- Study partner such as a spouse or close friend willing to attend study visits
This is a long-term study (5 to 8 years) that includes visits to our clinic in Greensboro with annual PET and MRI imaging. Visits are usually weekday mornings and can last several hours. Participants must have a dedicated study partner (spouse, relative or close friend) who can also attend the study visits. Payment for time and travel is included at each visit. Additional travel support for participants living outside the Greensboro area may be available
Alzheimer’s disease is a disorder that destroys memory and other critical brain functions. More than 5 million Americans have Alzheimer’s, and it is the sixth leading cause of death in the United States, and the only one without a cure.
Your genes may increase the likelihood of developing Alzheimer’s, but do not guarantee it will happen. Researchers have found several genes that increase the risk of Alzheimer’s. APOE-e4 is the first risk gene identified and remains the one with strongest impact.
We are looking for people who have this specific elevated genetic risk of developing Alzheimer’s Disease to take part in this research program. Having a history of Alzheimer’s Disease in your immediate family may be a related indicator. Before joining the study, you will be asked to take a quick cheek swab test to determine if you have specific genes that place you at increased risk for Alzheimer’s. You will have the opportunity for genetic counseling before the swab and before results are disclosed to you.
You may benefit from potential new therapies in a clinical trial before they are generally available and you will most definitely be helping improve healthcare options for everyone.